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For successful mitochondrial transgene expression, an optimal packaging exogenous DNA is an
important issue. We report herein on the effects of DNA packaged with mitochondrial transcription
factor A (TFAM), which packages mitochondrial DNA (mtDNA), on the transcription process. Our ini-
tial ﬁndings indicated that the transcription of the TFAM/DNA complex was activated, when the
complex was formed at an optimal ratio. We also found that TFAM has a signiﬁcant advantage over
protamine, a nuclear DNA packaging protein, from the viewpoint of transcription efﬁciency. This
result indicates that TFAM can be useful packaging protein for exogenous DNA to achieve mitochon-
drial transgene expression.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
It has been reported that mutations and defects in the mito-
chondrial genome (mtDNA) can form the basis for a variety of hu-
man diseases [1,2]. Therefore, mitochondrial gene therapy and
diagnosis would be expected to have substantial medical beneﬁts.
Mitochondrial transgene expression represents an attractive meth-
odology for achieving such an innovative medical goal. However,
successful examples of mitochondrial transgene expression have
not been reported to date. On the other hand, many reports have
appeared describing the use of a variety of applications for nuclear
transgene expression, including cationic liposomes, cell-penetrat-
ing peptides, polycations, etc. [3]. The formation of nanoparticles
between plasmid DNA (pDNA) and polycations have been
extensively investigated by many researchers, because it is known
that the manner in which pDNA is packaged with polycations has a
substantial effect on gene expression [4,5]. Protamine is well
known as a nuclear DNA condenser with a high transfection
activity [6,7].
mtDNA is packaged with speciﬁc core proteins in a complex re-
ferred to as a mitochondrial nucleoid, which has been implicated,al Societies. Published by Elsevier
. Harashima).not only in replication and transcription but also in the mainte-
nance of mtDNA [8–12]. Mitochondrial transcription factor A
(TFAM), one of the major components of nucleoids [8,13], was ini-
tially identiﬁed as a factor that activates transcription on heavy
and light strand mtDNA promoters (HSP and LSP) via sequence-
speciﬁc binding [14–17]. TFAM also binds DNA non-speciﬁcally, a
property that is essential for mtDNA packaging to play a crucial
role in mtDNA maintenance [18–21]. The expression levels of
TFAM and mtDNA are sufﬁciently interactive that the knockdown
of TFAM results in mtDNA depletion, and a reduction in mtDNA
copy number results in the degradation of TFAM [22,23]. Thus,
TFAM largely contributes to mtDNAmaintenance and would be ex-
pected to affect the replication and transcription.
Based on previous reports, we predicted that TFAM represents a
potentially optimal DNA condenser for mitochondrial transgene
expression. To validate this prediction, we compared DNA com-
plexes produced using TFAM and protamine in terms of their phys-
icochemical properties and transcription efﬁciency. We ﬁrst
prepared DNA complexes with TFAM and protamine at various mo-
lar ratios, and evaluated their physicochemical properties. We then
evaluated the extent to which transcription was affected by the
conformation of DNA packaged with DNA condensers using T7
RNA polymerase, an enzyme that is homologous to mitochondrial
RNA polymerase [24,25]. We also compared the transcription efﬁ-
ciency of long circular DNA (pDNA, 6445 bp) and short linear DNA
(1324 bp), to examine how the conformation in different-struc-
tured DNA packaged with TFAM affected transcription.B.V. Open access under CC BY-NC-ND license.
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2.1. Chemicals and materials
Protamine was purchased from Calbiochem (Darmstadt, Ger-
many). T7 RNA polymerase, ribonuclease inhibitor and SYBR Green
2 were purchased from Takara (Shiga, Japan). The pTriEx-3 Neo
vector (6445 bp) was obtained from Novagen (Madison, WI,
USA). pDNA was puriﬁed using a Qiagen EndoFree Plasmid Mega
Kit (Qiagen GmbH, Hilden, Germany). Ribonucleoside 50-triphos-
phates were from GE Healthcare Bio-Sciences (Piscataway, NJ,
USA). For the preparation of short linear DNA (1324 bp), pDNA
was digested by Tth111I and XbaI, and subjected to agarose gel
electrophoresis. Short linear DNA (1324 bp) was then extracted
and puriﬁed using a QIAquick Gel extraction kit (Qiagen GmbH).
2.2. Puriﬁcation of Recombinant TFAM
A fragment of human TFAM, corresponding to residues 43–246
(NCBI NP_003192) was ampliﬁed by PCR using the following pair
of primers; 50-ggggcatatgtcatctgtcttggcaagttg-30 (forward) and 50-
ggggctcgagtctacttttaacactcctca-30 (reverse). N-terminal protein re-
gion was reported to be mitochondrial targeting signal [26], and
was, therefore, removed from our construct. To express human
TFAM in Escherichia coli, the PCR fragment was cloned into pET-
28a (Novagen) that had been cleaved with NdeI and XhoI. Bacterial
cells harboring the plasmid were grown in LB medium containing
100 mg/L kanamycin, and expression was induced by treatment
with 1 mM isopropylthiogalactoside. The N-terminal His tag was
utilized for nickel-nitrilotriacetic acid afﬁnity puriﬁcation of the re-
combinant human TFAM according to the manufacturer’s instruc-
tions (Qiagen GmbH). The puriﬁed protein was ﬁnally dialyzed
against a buffer containing 10 mM Tris–HCl, pH 7.4, 150 mM NaCl,
1 mM dithiothreitol, and 20% glycerol. Protein concentrations were
determined using a BCA protein assay kit (Pierce, Rockford, IL,
USA).The puriﬁed protein was analyzed by SDS–PAGE to conﬁrm
that the recombinant human TFAM was purely prepared (Fig. S1).
2.3. Preparation of TFAM/DNA complex and protamine/DNA complex
For preparation of the DNA complex, DNA and TFAM (or prot-
amine) solutions at various molar ratios were mixed in 10 mM
HEPES buffer (pH 7.4) and the preparations then incubated at
25 C for 30 min. Dynamic light scattering (DLS) was employed to
determine the hydrodynamic diameters of the complexes in the
suspension (Zetasizer Nano ZS; Malvern Instruments, Herrenberg,
Germany). The f-average diameter (mean diameter) was calculated
from a cumulants analysis based on the intensity of the scattered
light. The f-potential, an indicator of surface potential, was deter-
mined electrophoretically using laser doppler velocimetry (Zeta-
sizer Nano ZS).
2.4. Electrophoretic mobility shift assay of TFAM/DNA complex and
protamine/DNA complex
To evaluate the packaging of DNA, TFAM/pDNA complex and
protamine/pDNA complex were subjected to agarose gel electro-
phoresis before and after treatment with the polyanion prepara-
tion. The samples were incubated for 30 min at 25 C with a
polyanion, i.e., a 1 mg/ml solution of poly (L-aspartic acid) (pAsp),
to release the pDNA. A 0.1 lg sample of pDNA was subjected to
electrophoresis. Electrophoresis was performed on a 1% agarose
gel in TAE (40 mM Tris–HCl, 40 mM acetic acid, 1 mM EDTA, pH
8.0) at 100 V for 30 min. The gel was stained with EtBr and ana-
lyzed by ImageQuant LAS 4000 (GE Healthcare Bio-Sciences).2.5. In vitro transcription assay
Transcription efﬁciencies of TFAM/DNA complex and prot-
amine/DNA complex were evaluated by in vitro transcription assay
using T7 RNA Polymerase as described below. DNA complexes con-
taining pDNA (30 fmol) or short linear DNA (60 fmol) were incu-
bated with T7 RNA Polymerase (17 U) at 37 C for 2 h, in a
reaction mixture (5.5 lL) containing incubation buffer (40 mM
Tris–HCl, pH 8.0, 8 mM MgCl2, 2.0 mM spermidine, 5.0 mM dithio-
threitol), 1.0 mM ribonuclease inhibitor and the four ribonucleo-
side 50-triphosphates (2 mM each). The reaction was terminated
by the addition of 14.5 lL of blocking buffer (29.6 mM Mops, pH
7.0, 7.4 mM sodium acetate, 1.5 mM EDTA, 18.5% formaldehyde,
74.1% formamide) and then incubated at 65 C for 15 min. The
reaction mixtures were analyzed by 18% formaldehyde–1% agarose
gel electrophoresis and stained with SYBR Green 2. Fluorograms
were obtained with an ImageQuant LAS 4000 to evaluate transcrip-
tion efﬁciency. Transcription efﬁciency was calculated as follows;
Transcription efficiency ¼ intensity of the transcript band from
samples=intensity of the transcript band from naked DNA:2.6. Investigation of transcription inhibition by ultraﬁltration and
in vitro transcription assay
pDNA were packaged with TFAM at various molar ratios, and
the resulting complexes were then subjected to ultraﬁltration to
remove unbound TFAM using Amicon Ultra Centrifugal Filters
(14,000g, 25 C,15 min). An in vitro transcription assay before
and after ultraﬁltration were performed, and as result, electropho-
resis gel data of transcripts after in vitro transcription reactions
were obtained (Fig. 4A). Relative transcription values were calcu-
lated as follows, the transcription efﬁciency of samples was nor-
malized by maximum transfection efﬁciency among the samples
(Fig. 4B).
3. Results
3.1. Physicochemical characteristics of TFAM/DNA complex and
protamine/DNA complex
We ﬁrst prepared pDNA complexes using several different mo-
lar ratios of pDNA (circular DNA, 6445 bp) and TFAM, or protamine
that is a nuclear DNA packaging protein, which is a polycationic
peptide rich in arginine residues [27]. Their particle sizes and f
potentials are summarized in Fig. 1. The particle sizes of the pDNA
complexes became smaller with increasing molar ratio in the case
of both TFAM and protamine (Fig. 1A), however, major differences
were observed in the case of f potentials (Fig. 1B). In the case of
protamine/pDNA complex, as the molar ratio increased, negatively
charged particles were converted into positively charged particles,
with diameters of 100 nm (Fig. 1, open diamonds). On the other
hand, negatively charged particles were formed when TFAM pack-
aged pDNA, and no positively charged ones were observed (Fig. 1,
closed diamonds). These results suggest that DNA packaging be-
tween TFAM and protamine occur in a different manner.
3.2. Investigation of the stabilities of TFAM/DNA complex and
protamine/DNA complex
We evaluated the stability of TFAM/pDNA complex and the
protamine/pDNA complex by means of an electrophoretic mobility
shift assay (Fig. 2). In this experiment, pDNA packaged with TFAM
or protamine at various molar ratios, and the pDNA complexes
were subjected to gel electrophoresis before and after treatment
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Fig. 2. Electrophoretic mobility shift assay of pDNA packaged with TFAM and
protamine. Gel shift analysis of pDNA packaged with TFAM (A) and protamine (B).
pDNA was packaged with TFAM or protamine at various molar ratios (molar
ratio = 0; lane 1 and 7, 1; lane 2 and 8, 50; lane 3 and 9, 100; lane 4 and 10, 500; lane
5 and 11, 1000; lane 6 and 12), and then the resulting products were subjected to
agarose gel electrophoresis with pAsp (lanes 1–6) or without pAsp (lanes 7–12).
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emitted as the result of EtBr intercalating with pDNA, when pDNA
is released from the complex or is loosely packaged with TFAM (or
protamine).
As shown in Fig. 2A, TFAM/pDNA complexes were detected by
EtBr at any molar ratio in the absence of pAsp, although their
mobilities were shifted to shorter values with increasing molar ra-
tio (Fig. 2A, lanes 1–6). We also observed a similar tendency in the
electrophoretic mobility shift of pDNA after pAsp treatment
(Fig. 2A, lanes 7–12). On the other hand, the stability of the pDNA
complex formed with protamine was quite different from that
formed with TFAM (Fig. 2B). Protamine/pDNA complexes formed
at molar ratios of 500 or more were undetectable by EtBr in the ab-
sence of pAsp (Fig. 2B, lanes 5 and 6), suggesting that pDNA is
tightly packaged at high molar ratios. We also observed the release
of pDNA from the protamine/pDNA complex after pAsp treatment
(Fig. 2B, lanes 7–12), suggesting that electrostatic interactions be-
tween pDNA and protamine are major contributors to the packag-
ing pDNA.
3.3. Comparison of the transcription efﬁciencies between TFAM/DNA
complex and protamine/DNA complex
We examined the issue of how transcription efﬁciency was af-
fected by the conformation of the pDNA packaged with TFAM
(Fig. 3A). Transcription efﬁciency was estimated by using T7 RNA
polymerase, an enzyme that is homologous to mitochondrial RNA
polymerase [24,25]. The transcription from pDNA packaged with
TFAM was activated in the optimal molar ratio, and an approxi-
mate twofold increase in transcription efﬁciency was found com-A 400
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Fig. 1. Characteristics of pDNA packaged with TFAM or protamine. pDNA were
packaged with TFAM (closed symbols) and protamine (open symbols) at various
molar ratios, and their diameters (A) and f potentials (B) were then measured. Data
are presented as the mean ± SD (n = 3).pared to the naked pDNA (Fig. 3A, closed diamonds). We also
observed a decrease in the transcription efﬁciencies, when pDNA
was packaged with TFAM at molar ratios of 500 and more. On
the other hand, in the case of protamine, no activation of transcrip-
tion was observed when pDNA was packaged at any molar ratio,
and the transcription was progressively inhibited with increasing
molar ratio (Fig. 3A, open diamonds).
3.4. Evaluation of transcription efﬁciency of different structured DNA
packaged with TFAM
To determine whether the transcriptional activation of DNA
packaged with TFAM is inﬂuenced by the structure of DNA, we
compared the transcription efﬁciency of a TFAM/DNA complex in
the case of pDNA (circular structure, 6445 bp) and short linear
DNA (linear structure, 1324 bp) preparations. Activation and inhi-
bition of transcription were observed in the case of both pDNA
and short linear DNA, but the optimal molar ratio for activating
transcription was different (Figs. 3A, B, closed symbols). The tran-
scription efﬁciency of pDNA was the highest when pDNA was
packaged at a molar ratio of 375 (Fig. 3A, closed diamonds), while,
for short linear DNA, the highest value was observed at a molar ra-
tio of 75 (Fig. 3B, closed triangles). The highest transcription efﬁ-
ciency of the TFAM/pDNA complex was 1.8-fold greater than that
for naked pDNA, while the value for short linear DNA was 1.3-fold.
A previous report showed that super coiled DNA was activated to a
greater extent by TFAM than relaxed circular DNA [28]. It seemed
that the conformational change for transcription activation might
be limited to linear DNA. In the case of protamine, the transcription
of the DNA complex was greatly inhibited and no activation was
found in the case of both pDNA and short linear DNA (Fig. 3A, B,
open symbols).
Based on the data shown in Fig. 3A, B (closed symbols), we con-
verted the molar ratios to the base-pair intervals required to TFAM
to bind to DNA (bp intervals) on the X-axis (Fig. 3C, closed
Fig. 3. In vitro transcription assay of DNA packaged with TFAM and protamine. pDNA (A, circular structure, 6445 bp) and short linear DNA (B, linear structure, 1324 bp) were
packaged with TFAM and protamine at various molar ratios, and then subjected to an in vitro transcription assay. Electrophoresis gel data for transcripts after in vitro
transcription reactions (upper part). Transcription efﬁciencies of DNA packaged with TFAM (closed symbols) and protamine (open symbols) were calculated based on the
relative intensity of transcript band (lower part). Data are presented as the mean ± SD (n = 3). Based on the data shown in Fig. 3A, B (closed symbols), we converted the molar
ratios to base-pair intervals that TFAM binds to DNA (bp intervals) in the X-axis (C). Closed diamonds and closed triangles indicate the values using pDNA and short linear
DNA, respectively. Data are presented as the mean ± SD (n = 3).
148 R. Furukawa et al. / FEBS Open Bio 2 (2012) 145–150diamonds, pDNA; closed triangles, short linear DNA).The base-pair
intervals were calculated, when a DNA complex was formed at the
optimal molar ratio for transcriptional activation (see Supplemen-
tary material for details).The values were calculated to be 17.1 and
17.6 in the case of pDNA and short linear DNA, respectively. These
values are in general agreement with values previously reported by
Kang and co-workers. They showed that one molecule of TFAM for
every 20 bp activated transcription by in vitro transcription using
mitochondrial RNA polymerase and mtDNA [21,28]. Based on this
stoichiometric consideration, we speculated that transcriptionmight be activated at the optimal DNA-conformation, when TFAM
binds to DNA at the appropriate interval, as shown in Fig. 5A.
3.5. Investigation of transcription inhibition by excess TFAM using
in vitro transcription assay
At high molar ratios, the transcription of DNA packaged with
TFAM was inhibited (Fig. 3A, B). In such situation, a number of un-
bound TFAM molecules might interfere with the transcription
reaction by T7 RNA polymerase. To validate this consideration, a
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Fig. 4. In vitro transcription assay of a TFAM/pDNA complex before and after
ultraﬁltration. Electrophoresis gel data of transcripts after in vitro transcription
reactions (A). pDNA were packaged with TFAM at various molar ratios (molar
ratio = 0; lane 1 and 9, 10; lane 2 and 10, 50; lane 3 and 11, 100; lane 4 and 12, 250;
lane 5 and 13, 375; lane 6 and 14, 500; lane 7 and 15, 1000; lane 8 and 16), and then
subjected to in vitro transcription assay before ultraﬁltration (lanes 1–8) and after
ultraﬁltration (lanes 9–16). Relative transcription value was calculated as follows
(B), transcription efﬁciency of samples was normalized by maximum transfection
efﬁciency among samples. Relative transcription values are indicated before (closed
symbols) ultraﬁltration and after (open symbols) ultraﬁltration. Data are presented
as the mean ± SD (n = 3).
Fig. 5. Schematic illustration of DNA packaged with TFAM and the transcriptional
manner. TFAM might form active DNA conformation for the transcription process,
where DNA is bent or supercoiled for recruiting T7 RNA polymerase (T7 RNAP) (A).
On the other hand, the overpackaging of DNA by excess TFAM would inhibit
transcription, because T7 RNA polymerase might be inaccessible to the T7 promoter
(B).
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after removing unbound TFAM by ultraﬁltration. pDNA were pack-
aged with TFAM at various molar ratios, and then subjected to
in vitro transcription assay before and after ultraﬁltration to re-
move unbound TFAM. Fig. 4A shows electrophoresis gel data of
transcripts before ultraﬁltration (Fig. 4A, lanes 1–8) and after ultra-
ﬁltration (Fig. 4A, lanes 9–16). Relative transcription value was
normalized by maximum transfection efﬁciency among samples
(Fig. 4B, closed diamonds, before ﬁltration; open diamonds, after
ﬁltration).
If unbound TFAM interferes with the transcription reaction by
T7 RNA polymerase, the transcription would be expected to be
accelerated after the removal of unbound TFAM. However, the
quantitative data showed that the transcription was inhibited to
the same extent both before and after ultraﬁltration (Fig. 4), indi-
cating that transcriptional inhibition was not largely involved with
the interference of transcription reaction by T7 RNA polymerase.
This supports the view that the inhibition of transcription by TFAM
is dependent on another factor, excess TFAM might bind to DNA
and, as a result, decrease the recognition afﬁnity of the T7 pro-
moter by T7 RNA polymerase via the overpackaging of DNA
(Fig. 5B).
4. Discussion
We ﬁrst investigated the physicochemical properties of pDNA
complexes when packaged with TFAM and protamine. In the case
of protamine, negatively charged particles were converted into
positively charged particles at a molar ratio of 500 (Fig. 1B, open
diamonds). In this electrostatic inversion point, which is calculated
to be a ± charge ratio of 2.4, excess protamine would contribute to
the formation of positively charged particles. On the other hand, in
the case of TFAM, the f potentials of the pDNA complexes were
negatively charge at all molar ratios (Fig. 1B, closed diamonds).
TFAM possesses high mobility group domains that contain both
cationic and anionic amino residues [13,29]. Based on our results
and this report, we conclude that the binding of cationic amino res-
idues in TFAM to DNA is possible and, when this occurs, the anionic
amino residues would be displayed on the surface of the TFAM/
pDNA complex.
Electrophoretic mobility shift assay data showed that pDNA
was efﬁciently released from a protamine/pDNA complex in the
presence of pAsp (Fig. 2B, lanes 7–12), whereas pDNA release
was not observed in the case of the TFAM/pDNA complex with
pAsp treatment (Fig. 2A, lanes 7–12). It is presumed that pAsp
might not be accessible to the TFAM/pDNA complex, because the
TFAM/pDNA complex is negatively charged. In addition, EtBr was
able to intercalate with the TFAM/pDNA complex, even at high mo-
lar ratios (Fig. 2A, lanes 5 and 6), although the protamine/pDNA
complex was not detected under the same conditions (Fig. 2B,
lanes 5 and 6). These results suggest that a TFAM/pDNA complex
might be more loosely formed compared to a protamine/pDNA
complex.
From the viewpoint of the unique structure of TFAM, we consid-
ered the reasons for why transcription is activated at speciﬁc con-
ditions as shown in Fig. 3. One possibility is that TFAM might form
a DNA conformation that is beneﬁcial for activating transcription
via non-speciﬁc binding, in which DNA would be easily recognized
by T7 RNA polymerase, as shown in Fig. 5A. A recent crystallo-
graphic analysis of TFAM provides support for this possibility
[29]. In the study, the crystal structure of full-length TFAM in com-
plex with an oligonucleotide containing the LSP sequence was ana-
lyzed and the results suggest that TFAM causes the LSP to bend,
thus creating an optimal DNA arrangement for transcriptional ini-
tiation. It was hypothesized that TFAM might play a role in the
150 R. Furukawa et al. / FEBS Open Bio 2 (2012) 145–150structural change to strengthen the afﬁnity of mitochondrial RNA
polymerase for mtDNA, resulting in transcription activation.
Our ﬁndings indicated that DNA packaged with TFAM would
have a great advantage over one packaged with protamine from
the viewpoint of transcription efﬁciency. We also found that the
TFAM could activate the transcription process with packaged
DNA at the optimal molar ratio of DNA/TFAM. Moreover, a note-
worthy point is that this study is the ﬁrst trial to evaluate the effect
of DNA packaged with TFAM on the transcription process using T7
RNA polymerase and DNA containing the T7 promoter. Collec-
tively, our ﬁndings would largely contribute to the development
of mitochondrial transgene methodology. In the future, we plan
to investigate the function of DNA packaged with TFAM in mito-
chondria of living cells, using our mitochondrial matrix delivery
system, a MITO-Porter that delivers cargoes into the mitochondrial
matrix via membrane fusion [30–33]. Studies in this area are cur-
rently underway.
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